Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction

International Journal of Cardiology

Volumn 202, Issue , 2016, Pages 517-518

  Freixa, Xavier ^a   Hernández, Marco ^a   Farrero, Marta ^a   Sitges, Marta ^a   Jiménez, Gustavo ^a   Regueiro, Ander ^a   Fita, Guillermina ^a   Tatjer, Irene ^a   Andrea, Rut ^a   Martín Yuste, Victoria ^a   Brugaletta, Salvatore ^a   Masotti, Mónica ^a   Sabaté, Manel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Left ventricle dysfunction; Levosimendan; MitraClip; Mitral regurgitation; Percutaneous mitral repair

Indexed keywords

LEVOSIMENDAN; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

ADULT; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; IMPLANTABLE CLIP; LETTER; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; OBSERVATIONAL STUDY; PRIORITY JOURNAL; AGED; DEVICES; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART VALVE REPLACEMENT; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MULTIMODALITY CANCER THERAPY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PYRIDAZINES; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84960172598     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.09.056     Document Type: Article

References (9)

1. J. Ross Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy J. Am. Coll. Cardiol. 5 1985 811 826
2. A.R. Doyle, A.K. Dhir, A.H. Moors, and R.D. Latimer Treatment of perioperative low cardiac output syndrome Ann. Thorac. Surg. 59 1995 S3 S11
3. G. Melisurgo, S. Ajello, F. Pappalardo, and et al. Afterload mismatch after MitraClip insertion for functional mitral regurgitation Am. J. Cardiol. 113 2014 1844 1850
4. R. Levin, M. Degrange, C. Del Mazo, E. Tanus, and R. Porcile Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass Exp. Clin. Cardiol. 17 2012 125 130
5. A. Tasouli, K. Papadopoulos, T. Antoniou, and et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg. 32 2007 629 633
6. G. Nickenig, R. Estevez-Loureiro, O. Franzen, and et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry J. Am. Coll. Cardiol. 64 2014 875 884
7. K. Boerlage-vanDijk, E.M. Wiegerinck, M. Araki, and et al. Predictors of outcome in patients undergoing MitraClip implantation: an aid to improve patient selection Int. J. Cardiol. 189 2015 238 243
8. J. Tamargo, and J. Lopez-Sendon Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure Rev. Esp. Cardiol. 57 2004 447 464
9. J.G. Laffey, J.F. Boylan, and D.C. Cheng The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist Anesthesiology 97 2002 215 252